SE0104332D0 - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
SE0104332D0
SE0104332D0 SE0104332A SE0104332A SE0104332D0 SE 0104332 D0 SE0104332 D0 SE 0104332D0 SE 0104332 A SE0104332 A SE 0104332A SE 0104332 A SE0104332 A SE 0104332A SE 0104332 D0 SE0104332 D0 SE 0104332D0
Authority
SE
Sweden
Prior art keywords
iquest
chloro
therapeutic agents
obesity
psychiatric
Prior art date
Application number
SE0104332A
Other languages
Swedish (sv)
Inventor
Kristina Berggren
Michael Wilstermann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0104332A priority Critical patent/SE0104332D0/en
Publication of SE0104332D0 publication Critical patent/SE0104332D0/en
Priority to PCT/GB2002/005736 priority patent/WO2003051850A1/en
Priority to AU2002352420A priority patent/AU2002352420A1/en
Priority to TW091136670A priority patent/TW200410693A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

The present invention relates to compound of formula (I) and pharmaceutically acceptable salts, solvates and crystalline forms thereof, in which R&iquest;1< represents cyclohexyl, 1-piperidinyl or phenyl; R&iquest;2? represents H, chloro, bromo, methyl or methoxy; and when R&iquest;3? represents H, R&iquest;4? represents H or chloro; and when R&iquest;3? represents chloro, R&iquest;4? represents H or chloro; to processes for preparing such compounds, to their use in the treatment of obesity, psychiatric and neurological disorders particularly obesity, to methods for their therapeutic use and to pharmaceutical compositions containing them.
SE0104332A 2001-12-19 2001-12-19 Therapeutic agents SE0104332D0 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SE0104332A SE0104332D0 (en) 2001-12-19 2001-12-19 Therapeutic agents
PCT/GB2002/005736 WO2003051850A1 (en) 2001-12-19 2002-12-18 Pyrazine compounds and pharmaceutical compositions containing them
AU2002352420A AU2002352420A1 (en) 2001-12-19 2002-12-18 Pyrazine compounds and pharmaceutical compositions containing them
TW091136670A TW200410693A (en) 2001-12-19 2002-12-19 Therapeutic agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0104332A SE0104332D0 (en) 2001-12-19 2001-12-19 Therapeutic agents

Publications (1)

Publication Number Publication Date
SE0104332D0 true SE0104332D0 (en) 2001-12-19

Family

ID=20286431

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104332A SE0104332D0 (en) 2001-12-19 2001-12-19 Therapeutic agents

Country Status (4)

Country Link
AU (1) AU2002352420A1 (en)
SE (1) SE0104332D0 (en)
TW (1) TW200410693A (en)
WO (1) WO2003051850A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc Substituted 2,3-diphenyl pyridines
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
US7405221B2 (en) 2002-09-27 2008-07-29 Merck & Co., Inc. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
GB0314049D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1641779A1 (en) * 2003-06-18 2006-04-05 AstraZeneca AB 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
EP1644335A4 (en) 2003-07-11 2008-06-04 Bristol Myers Squibb Co Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US7326706B2 (en) 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
US7517900B2 (en) 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
BRPI0507120A (en) 2004-01-28 2007-06-19 Hoffmann La Roche compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases that are associated with cb1 receptor modulation and their use
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
BRPI0517653A (en) 2004-11-09 2008-10-14 Hoffmann La Roche compounds, process for their manufacture, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases and use of the compounds
WO2006106054A1 (en) 2005-04-06 2006-10-12 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
JP2008536950A (en) * 2005-04-18 2008-09-11 ニューロジェン・コーポレーション Substituted heteroaryl CB1 antagonists
WO2007003962A2 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
US7897601B2 (en) * 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
FR2904827B1 (en) 2006-08-11 2008-09-19 Sanofi Aventis Sa 5,6-BISARYL-2-PYRIDINE CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE AS UROTENSIN II RECEPTOR ANTIGANISTS
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
EP2450350A1 (en) 2006-10-04 2012-05-09 F. Hoffmann-La Roche AG 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents
RS52065B (en) 2007-01-04 2012-06-30 Prosidion Ltd Piperidine gpcr agonists
CA2674360A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
CL2008000017A1 (en) 2007-01-04 2008-08-01 Prosidion Ltd COMPOUNDS DERIVED FROM NITROGEN AND OXYGEN HETEROCICLES, GPCR AGONISTS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF OBESITY, DIABETES, METABOLIC SYNDROME, HYPERLIPIDEMIA, TOLERANCE
CL2008000018A1 (en) 2007-01-04 2008-08-01 Prosidion Ltd COMPOUNDS DERIVED FROM NITROGEN AND OXYGEN HETEROCICLES, GPCR AGONISTS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF OBESITY, DIABETES, METABOLIC SYNDROME, HYPERLIPIDEMIA, TOLERANCE
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
FR2927330B1 (en) 2008-02-07 2010-02-19 Sanofi Aventis 5,6-BISARYL-2-PYRIDINE CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE AS ANTAGONISTS OF UROTENSIN II RECEPTORS
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004308A1 (en) * 1987-11-12 1989-05-18 Terumo Kabushiki Kaisha Pyrazine derivatives and medicinal preparation containing same
WO1992002513A1 (en) * 1990-08-06 1992-02-20 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds

Also Published As

Publication number Publication date
WO2003051850A1 (en) 2003-06-26
TW200410693A (en) 2004-07-01
AU2002352420A1 (en) 2003-06-30

Similar Documents

Publication Publication Date Title
SE0104332D0 (en) Therapeutic agents
IS2293B (en) Aryl fused azapolycyclic compounds
MXPA03011638A (en) 4-piperazinylindole derivatives with 5-ht6 receptor affinity.
JO2371B1 (en) 4-phenyl -pyridine derivatives
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
RS28004A (en) Azabicycle-substituted fused- heteroaryl compounds for the treatment of disease
YU95102A (en) Substituted bicyclic derivatives for the treatment of abnormal cell growth
MXPA04000278A (en) Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury.
HK1070054A1 (en) Arylsulfonyl derivatives with5-ht6 receptor affinity
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
SE0400043D0 (en) New compounds
PL361282A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
TW200509933A (en) Therapeutic agents
ATE268337T1 (en) C11-CARBAMATES OF ANTIBACTERIAL MACROLIDS
BG104983A (en) Aryl fused azapolycyclic compounds
MXPA04005313A (en) Aminotetralin derivatives as muscarinic receptor antagonists.
MXPA04005076A (en) 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists.
DE69933885D1 (en) TRIPHENYLBUTEN DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
CA2374643A1 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinylaminomethylchroman derivatives as substance p antagonists
ZA200300218B (en) Novel N-(2-phenyl-3-aminopropyl)naphtamides.
ATE250027T1 (en) AZETIDINE CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISEASES
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
DK1049670T3 (en) Azetidine carboxamide derivatives for the treatment of CNS disorders
YU79401A (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives